Sumitomo Pharma (4506) Q1 2025 earnings summary

Executive summary

• Q1 FY2024 revenue rose 19.8% year-over-year to ¥90.7B, driven by strong sales of ORGOVYX®, MYFEMBREE®, and GEMTESA®, and favorable currency effects.

• Net profit attributable to owners reached ¥15.9B, reversing a ¥38.9B loss in Q1 FY2023, due to higher revenue and reduced expenses.

• Core operating loss narrowed sharply to ¥0.9B from ¥33.5B planned, reflecting cost reductions and business structure improvements.

• Operating loss improved to ¥-3.1B from ¥-51.6B year-over-year, aided by lower business structure improvement expenses.

• Progress made in R&D, including NDA preparation for Parkinson's therapy and clinical collaborations in oncology.

Financial highlights

• Revenue: ¥90.7B (up ¥15.0B year-over-year); gross profit: ¥55.7B (up ¥10.5B year-over-year).

• SG&A expenses decreased to ¥43.8B (down ¥18.0B year-over-year); R&D expenses down to ¥12.8B (down 52.9% year-over-year).

• Operating profit improved to ¥-3.1B from ¥-51.6B year-over-year.

• Basic earnings per share was ¥40.11, up from a loss of ¥97.82 per share.

• Cash and cash equivalents at period-end were ¥78.4B.

Outlook and guidance

• FY2024 revenue target for three key products set at ¥130B, with Q1 progress on track.

• Full-year revenue forecast is ¥338.0B, with a projected core operating loss of ¥16.0B and net loss attributable to owners of ¥13.0B.

• No revision to full-year forecasts as of Q1 FY2024; company aims to turn core operating profit positive and drive renewed growth.

• Continued focus on cost control, R&D prioritization, and maximizing product value.